116 related articles for article (PubMed ID: 9877245)
1. Human ovarian cancer xenografts in nude mice: chemotherapy trials with paclitaxel, cisplatin, vinorelbine and titanocene dichloride.
Villena-Heinsen C; Friedrich M; Ertan AK; Farnhammer C; Schmidt W
Anticancer Drugs; 1998 Jul; 9(6):557-63. PubMed ID: 9877245
[TBL] [Abstract][Full Text] [Related]
2. Effects of vinorelbine and titanocene dichloride on human tumour xenografts in nude mice.
Friedrich M; Villena-Heinsen C; Farnhammer C; Schmidt W
Eur J Gynaecol Oncol; 1998; 19(4):333-7. PubMed ID: 9744720
[TBL] [Abstract][Full Text] [Related]
3. Relationship between chemotherapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and expression of proliferation markers and tumour suppressor gene p53 in human ovarian cancer xenografts in nude mice.
Kolberg HC; Villena-Heinsen C; Deml MM; Kraemer S; Diedrich K; Friedrich M
Eur J Gynaecol Oncol; 2005; 26(4):398-402. PubMed ID: 16122187
[TBL] [Abstract][Full Text] [Related]
4. Human tumour xenografts in nude mice: chemotherapy trials with titanocene dichloride in different dosages.
Villena-Heinsen C; Friedrich M; Ertan AK; Schmidt W
Clin Exp Obstet Gynecol; 1998; 25(1-2):5-8. PubMed ID: 9743868
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.
Köpf-Maier P
Anticancer Res; 1999; 19(1A):493-504. PubMed ID: 10226588
[TBL] [Abstract][Full Text] [Related]
6. Anti-proliferative activity and mechanism of action of titanocene dichloride.
Christodoulou CV; Eliopoulos AG; Young LS; Hodgkins L; Ferry DR; Kerr DJ
Br J Cancer; 1998 Jun; 77(12):2088-97. PubMed ID: 9649119
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Ramsey SD; Moinpour CM; Lovato LC; Crowley JJ; Grevstad P; Presant CA; Rivkin SE; Kelly K; Gandara DR
J Natl Cancer Inst; 2002 Feb; 94(4):291-7. PubMed ID: 11854391
[TBL] [Abstract][Full Text] [Related]
8. Vinorelbine: a new promising drug in Hodgkin's disease.
Devizzi L; Santoro A; Bonfante V; Viviani S; Bonadonna G
Leuk Lymphoma; 1996 Aug; 22(5-6):409-14. PubMed ID: 8882953
[TBL] [Abstract][Full Text] [Related]
9. The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen: a phase I-II study of paclitaxel, cisplatin, and vinorelbine.
Lokich JJ; Anderson N; Bern M; Coco F; Dow E
Cancer; 1999 Jan; 85(2):499-503. PubMed ID: 10023721
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancer.
Cortes J; Rodriguez J; Calvo E; Gurpide A; Garcia-Foncillas J; Salgado E; Aramendia JM; Lopez-Picazo JM; Hernandez B; Hidalgo R; Aristu JJ; Brugarolas A; Martin-Algarra S
Am J Clin Oncol; 2004 Jun; 27(3):299-303. PubMed ID: 15170152
[TBL] [Abstract][Full Text] [Related]
11. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
[TBL] [Abstract][Full Text] [Related]
12. Combination effect of navelbine (vinorelbine ditartrate) with cisplatin against murine P388 leukemia and human lung carcinoma xenografts in mice.
Ashizawa T; Asada M; Kobayashi E; Okabe M; Gomi K; Hirata T
Anticancer Drugs; 1993 Oct; 4(5):577-83. PubMed ID: 8292816
[TBL] [Abstract][Full Text] [Related]
13. Re: Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Malayeri R
J Natl Cancer Inst; 2002 Aug; 94(15):1172; author reply 1172. PubMed ID: 12165643
[No Abstract] [Full Text] [Related]
14. Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
Lonial S; Arellano M; Hutcherson D; Langston A; Flowers C; Heffner LT; Winton E; Jo Lechowicz M; Waller EK
Leuk Lymphoma; 2006 Oct; 47(10):2155-62. PubMed ID: 17071490
[TBL] [Abstract][Full Text] [Related]
15. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
16. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Teicher BA; Chen V; Shih C; Menon K; Forler PA; Phares VG; Amsrud T
Clin Cancer Res; 2000 Mar; 6(3):1016-23. PubMed ID: 10741729
[TBL] [Abstract][Full Text] [Related]
17. Absence of major peripheral neuropathy in a phase II trial of ifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and paclitaxel.
Fleming GF; Waggoner SE; Rotmensch J; Langhauser C
Am J Clin Oncol; 2001 Feb; 24(1):52-7. PubMed ID: 11232950
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice.
Fichtner I; Pampillón C; Sweeney NJ; Strohfeldt K; Tacke M
Anticancer Drugs; 2006 Mar; 17(3):333-6. PubMed ID: 16520662
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice.
Chahinian AP; Mandeli JP; Gluck H; Naim H; Teirstein AS; Holland JF
J Surg Oncol; 1998 Feb; 67(2):104-11. PubMed ID: 9486781
[TBL] [Abstract][Full Text] [Related]
20. The current and future place of vinorelbine in cancer therapy.
Cvitkovic E; Izzo J
Drugs; 1992; 44 Suppl 4():36-45; discussion 66-9. PubMed ID: 1283849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]